[go: up one dir, main page]

MX2019002647A - Composiciones de tesofensina. - Google Patents

Composiciones de tesofensina.

Info

Publication number
MX2019002647A
MX2019002647A MX2019002647A MX2019002647A MX2019002647A MX 2019002647 A MX2019002647 A MX 2019002647A MX 2019002647 A MX2019002647 A MX 2019002647A MX 2019002647 A MX2019002647 A MX 2019002647A MX 2019002647 A MX2019002647 A MX 2019002647A
Authority
MX
Mexico
Prior art keywords
compositions
tesofensine
tesofensin
overweight
obesity
Prior art date
Application number
MX2019002647A
Other languages
English (en)
Other versions
MX381130B (es
Inventor
Racheboeuf Bruno
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of MX2019002647A publication Critical patent/MX2019002647A/es
Publication of MX381130B publication Critical patent/MX381130B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe composiciones de tesofensina, métodos para preparar las mismas y su uso en la preparación de medicamentos para la prevención y tratamiento de sobrepeso, obesidad y diabetes mellitus tipo 2.
MX2019002647A 2016-09-07 2017-09-07 Composiciones de tesofensina. MX381130B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16187596 2016-09-07
EP16187813 2016-09-08
PCT/EP2017/072462 WO2018046599A1 (en) 2016-09-07 2017-09-07 Tesofensine compositions

Publications (2)

Publication Number Publication Date
MX2019002647A true MX2019002647A (es) 2019-07-01
MX381130B MX381130B (es) 2025-03-12

Family

ID=59914436

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002647A MX381130B (es) 2016-09-07 2017-09-07 Composiciones de tesofensina.

Country Status (15)

Country Link
US (1) US9949964B2 (es)
EP (1) EP3509597A1 (es)
JP (1) JP2019526641A (es)
KR (1) KR20190050784A (es)
AU (1) AU2017324406A1 (es)
BR (1) BR112019004033A2 (es)
CA (1) CA3032349A1 (es)
CO (1) CO2019002853A2 (es)
CR (1) CR20190142A (es)
DO (1) DOP2019000052A (es)
EC (1) ECSP19024033A (es)
IL (1) IL264503A (es)
MX (1) MX381130B (es)
RU (1) RU2019109050A (es)
WO (1) WO2018046599A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2979279T3 (es) 2017-07-07 2024-09-25 Boehringer Ingelheim Vetmedica Gmbh Telmisartán para la profilaxis o el tratamiento de la hipertensión en gatos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
JP3238414B2 (ja) 1996-02-22 2001-12-17 ニューロサーチ・アクティーゼルスカブ トロパン―誘導体、その製造方法及びその使用方法
US5977158A (en) * 1996-11-28 1999-11-02 Novo Nordisk A/S Pharmaceutical formulations comprising levormeloxifene compounds
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US7125563B2 (en) * 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
DE102004004965B4 (de) 2004-01-31 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates
EP1779851A1 (en) 2005-10-31 2007-05-02 Boehringer Ingelheim Pharma GmbH & Co.KG Treatment of diabetes
EP2237781A2 (en) * 2007-12-20 2010-10-13 NeuroSearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity
US20120115837A1 (en) * 2009-04-30 2012-05-10 Takeda Pharmaceutical Company Limited Solid Preparation
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
JP6203760B2 (ja) 2012-02-16 2017-09-27 サニオナ・エー／エス 併用療法のための医薬組成物

Also Published As

Publication number Publication date
EP3509597A1 (en) 2019-07-17
WO2018046599A1 (en) 2018-03-15
BR112019004033A2 (pt) 2019-05-28
US9949964B2 (en) 2018-04-24
MX381130B (es) 2025-03-12
CR20190142A (es) 2019-05-22
KR20190050784A (ko) 2019-05-13
JP2019526641A (ja) 2019-09-19
CO2019002853A2 (es) 2019-08-20
RU2019109050A (ru) 2020-10-08
IL264503A (en) 2019-02-28
CA3032349A1 (en) 2018-03-15
AU2017324406A1 (en) 2019-05-02
DOP2019000052A (es) 2019-05-15
ECSP19024033A (es) 2019-04-30
US20180064700A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CY1122818T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-αλκυλ-8-αμινο-2-οξο-1,3-διαζα- σπε1ρο-[4.5]-δεκανιου
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CO2019004131A2 (es) Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
CL2021000930A1 (es) Piridazinas novedosas
CR20190131A (es) 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2018007128A (es) Composiciones para barnices dentales y metodos para su elaboracion y uso.
CO2019002853A2 (es) Composiciones de tesofensina
DK3886834T3 (da) Processes for preparing nitrosylated propanediols, compositions comprising the same, and medical uses thereof
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma